Successful completion of phase I clinical studies of patients with systemic lupus erythematosus and phase II clinical trials of patients with Sjogren's syndrome (both performed by Amgen Inc.)demonstrated the effectiveness of human anti-ICOSL mAb prezalumab [15, 16]. This evidence concerns the gene ICOSLG and systemic lupus erythematosus.